Xin Lang Cai Jing·2025-05-22 23:36Group 1 - Health元 announced that its subsidiary, Lijuz Group, plans to acquire 64.81% of Imexpharm Corporation for approximately 5.73 trillion VND (about 1.587 billion RMB), which represents 11.45% of Lijuz Group's latest audited net assets [1] - Imexpharm Corporation is a Vietnamese pharmaceutical company engaged in the research, production, and sales of drugs, including antibiotics and cardiovascular medications [1] - After the acquisition, Imexpharm will become a subsidiary of Lijuz Group, aiding in the expansion of the group's overseas market [1] Group 2 - Lijuz Group's revenue has been under pressure, with a reported revenue of 11.812 billion RMB in 2024, a decrease of 4.97% year-on-year, while net profit increased by 5.50% to 2.061 billion RMB [2] - The decline in revenue is attributed to price reductions from national medical insurance negotiations affecting key products, as well as decreased sales in antiviral products following reduced demand due to COVID-19 and flu [2] - Health元 also reported a revenue of 15.619 billion RMB in 2024, down 6.17% year-on-year, with a net profit of 1.387 billion RMB, a decrease of 3.90% [2] Group 3 - Lijuz Group is accelerating its international expansion to enhance its risk resilience, with products already covering Southeast Asia, South America, the Middle East, and Africa [3] - The company has initiated the construction of an active pharmaceutical ingredient factory in Indonesia to support local and international production, aiming to reduce costs and improve market responsiveness [3] - In 2024, Lijuz Group achieved overseas revenue of 1.724 billion RMB, a year-on-year increase of 9.69%, accounting for 14.59% of total revenue, which is a 2 percentage point increase from 2023 [3]